Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 113

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 113
---
There were no net cash
used in investing activities during the years ended December 31, 2024 and 2023.

Net cash used in financing activities

Net cash provided by financing
activities increased by $0.2 million, to approximately $0.5 million for the year ended December 31, 2024 compared to $0.3 million for
the year ended December 31, 2023. This increase was due to higher proceeds from short-term loan in 2024.

Funding Requirements

We have incurred losses
from operations since the inception, resulting in an accumulated deficit on December 31, 2024 and December 31, 2023 of approximately
$41.7 million and $46.9 million, respectively. We anticipate that we will continue to incur net losses for the foreseeable future.
We believe that our existing cash and cash equivalents, without giving effect to the proceeds from this offering, will be sufficient
to fund our projected cash needs until June 2025. To meet future capital needs, we would need to raise additional capital through equity
or debt financing or other strategic transactions. However, any such financing may not be on favorable terms or even available to us.
Our failure to obtain sufficient funds on commercially acceptable terms when needed would have a material adverse effect on our business,
results of operations and financial condition. Our forecast of the period of time through which our financial resources will be adequate
to support our operations is a forward-looking statement that involves risks and uncertainties, and the actual amount of our expenses
could vary materially and adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to
be wrong, and our expenses could prove to be significantly higher than we currently anticipate.

Our future capital requirements
will depend on many factors, including, but not limited to:

| ● | the progress and costs of our research and development activities; |

| ● | the costs of development and expansion of our operational infrastructure; |

| ● | our ability, or that of our collaborators, to achieve development milestones and other events or developments under potential future licensing agreements; |

| ● | the amount of revenues and contributions we receive under future licensing, collaboration, development and commercialization arrangements with respect to our technologies; |

| ● | the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; |

| ● | the costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves, once our technologies